The neurological biomarkers market consists of proteins, gene expressions, and small molecules that can be measured in different biofluids like blood, urine and cerebrospinal fluid to determine normal as well as abnormal biological processes associated with various neurological disorders. These biomarkers help in evaluating the biological response to a therapeutic intervention thus playing a pivotal role in drug development processes. Neurological biomarkers are extensively used for diagnostic purposes, drug discovery as well as monitoring treatment response and disease progression in conditions like Alzheimer's disease, Parkinson's disease and Traumatic brain injury amongst others.
The global neurological biomarkers market is estimated to be valued at US$ 13609.32 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the neurological biomarkers market are Knauf Gips KG, LafargeHolcim, National Gypsum Company, Saint-Gobain Group, Yoshino Gypsum Co., Ltd., ACG Materials, Anhydritec, BNZ Materials Inc., American Gypsum, Gyptec Iberica. These players are focusing on new product launches and regulatory approvals to strengthen their market presence. For instance, in 2023, ACG Materials received FDA approval for Neurofilament Light Chain (NfL) test kit which is used as a blood test to detect signs of neurodegeneration.
The growing prevalence of neurological disorders across the globe is anticipated to drive the demand for neurological biomarkers. As per estimates, over 1 billion people suffer from neurological disorders worldwide. Neurological conditions pose significant economic and societal burden therefore early and accurate diagnosis is crucial. Neurological biomarkers help in early and non-invasive detection of various neurological diseases thus fueling their adoption.
Advancements in omics technologies such as proteomics, genomics and metabolomics have facilitated the discovery and validation of novel neurological biomarkers. Companies are undertaking collaborative R&D for developing highly sensitive and specific biomarkers that can be detected in easily accessible biofluids. This is expected to boost the development of liquid biopsy tests for real-time, non-invasive monitoring of neurological diseases.
Market Trends
Increasing adoption of personalized medicine approaches: Use of Neurological Biomarkers Size help clinicians deliver personalized treatment plans based on individual patient's disease mechanism, severity and therapeutic response. This is expected to be a key trend in the market.
Rising demand for non-invasive diagnostic tools: Companies are focused on developing non-invasive diagnostic tools involving blood or urine tests using neurological biomarkers. This prevents unnecessary brain surgery for diagnosis and increases adoption.
Market Opportunities
Emerging economies in Asia Pacific and Latin America: These regions are expected to present lucrative opportunities for market players owing to growing healthcare investment, rising medical tourism and increasing prevalence of neurological disorders.
Integration of AI and machine learning: Integration of AI and machine learning technologies can help identify unique biomarker signatures for precision diagnosis and real-time monitoring of neurological conditions thereby presenting major opportunities.
Impact of COVID-19 on Neurological Biomarkers Market:
The COVID-19 pandemic has adversely impacted the global neurological biomarkers market. The restrictions imposed due to the spread of the virus like lockdowns and social distancing has disrupted the research activities and slowed down the development of new diagnostic tools and therapies. This has hampered the market growth during 2020. The demand for biomarkers for conditions like Alzheimer's disease, Parkinson's disease, traumatic brain injury, multiple sclerosis, epilepsy reduced significantly due to postponed diagnosis and elective surgeries.
However, companies are focusing on developing biomarkers for COVID-19 to better understand the neurological complications associated with the disease. The biomarkers are being studied to examine whether they can help detect coronavirus infection or assess the risk of neurological illness. Researchers are investigating various blood-based proteins and autoantibodies as potential COVID-19 neurological biomarkers. As the pandemic eases with increased vaccination, the market is expected to rebound steadily as research and clinical trials regain momentum to advance therapeutic development for neurological disorders. Telemedicine is also aiding the market's recovery by enabling remote consultations and management of chronic conditions.
In terms of regional distribution of value, North America dominates the neurological biomarkers market due to increasing prevalence of neurological disorders, rising healthcare expenditure, early diagnostic rates and availability of advanced healthcare facilities. The presence of key market players and well-established research infrastructure in the region further drives the market.
Asia Pacific is projected to be the fastest growing market for neurological biomarkers during the forecast period owing to growing geriatric population, improving healthcare infrastructure, increasing per capita healthcare expenditure in emerging Asian countries like India and China. Rising awareness about neurological diseases and expanding diagnostic capabilities in these countries offer lucrative growth opportunities for market players in Asia Pacific.
For More Details On The Report, Read: https://www.newsstatix.com/neurological-biomarkers-market-poised-to-garner-significant-growth-by-2030/
Explore More Related Trending Articles: https://coolbio.org/system-on-a-chip-soc-the-future-of-electronics/
